Address: Galileiweg 8 (Formerly Wassenaarseweg 72)
2333 BD Leiden ,Netherlands
Tel: 071-332-2030
Top Institute Pharma (TI Pharma) is a public-private partnership in which scientific and business worlds work together on groundbreaking, multidisciplinary research aimed at improving the development of socially valuable medicines. This research precedes the stage in which companies develop individual medicines commercially. Our institute acts as an essential link in combining the knowledge present in science and industry. Collaboration within our research projects provides unique opportunities to strengthen the scientific foundation of pharmaceutical research in the Netherlands
Our research projects are, for a large part, focused on research that is difficult or impossible for individual companies to perform. Our research portfolio is based on the disease areas as specified in Priority Medicines, a report by the World Health Organization (WHO). These projects create knowledge that is important for better, faster and less-expensive development of valuable new medicines.
There is a very interesting history behind the origins of Top Institute Pharma (TI Pharma) as it aligned the interests of both the World Health Organization (Priority Medicines) and the…
Floris Van Haselen, Business Development Director Europe for O&M Movianto, one of the rare logistics companies to be fully specialized and to only operate in the healthcare sector, explains how the company…
Peter Schoevers, CEO and co-founder of Julius Clinical, explains how this innovative and thriving organization allies the academic strength of an ARO with the business-oriented leadership of a CRO. Julius…
Isabelle de Walsche, Managing Director of Gedeon Richter Benelux, provides us with an update on the development of this striving and ambitious player in the women’s healthcare field and shares…
Roeland Van Dam, CEO of Bilthoven Biologicals, a historical Dutch company which remains at the forefront of vaccine production, explains how being integrated into the Serum Institute of India has…
Rob de Roock, Director CL Healthcare for UPS Europe, gives us a brief outline of the current market dynamics impacting the booming European healthcare logistics industry and explains how UPS…
Han Brouwer, General Manager for Actelion in the Netherlands, explains how Opsumit’s successful market launch has strengthened Actelion’s leadership position in the pulmonary arterial hypertension (PAH) field. He calls for…
Bart van de Kerkhof highlights how Covidien’s acquisition will drive Medtronic to new heights thanks to a broader product portfolio. Medtronic is already piloting projects and cooperating with key stakeholders to…
Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help…
Amgen Netherlands is preparing to launch five new products next year, including their leading cardiovascular biotech product Repatha and recently announced the acquisition of the Dutch biotech Dezima. General manager…
Maikel Beerens, CEO and founder of Xilloc, a promising Dutch company that designs patient-specific implants, anatomical models and surgical guides for bone reconstruction or augmentation with the help of 3-D…
Michiel van der Veen, CEO of GenKey, a global player in biometric identity management based in Eindhoven, explains how both the healthcare industry and public health schemes could benefit from…
Menno Kok and Roel Kamerling, Director and CIO of Medical Delta, a life sciences, health & technology innovation cluster around Leiden, Delft and Rotterdam in the West of the Netherlands,…
See our Cookie Privacy Policy Here
